KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Non-Current Assets (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Other Non-Current Assets for 15 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets changed N/A to $1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Dec 2025, changed N/A year-over-year, with the annual reading at $1.4 million for FY2025, N/A changed from the prior year.
  • Other Non-Current Assets for Q4 2025 was $1.4 million at Supernus Pharmaceuticals, down from $62.4 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $403.8 million in Q1 2023, with the low at $1.4 million in Q4 2025.
  • Average Other Non-Current Assets over 5 years is $59.7 million, with a median of $39.8 million recorded in 2022.
  • The sharpest move saw Other Non-Current Assets surged 5523.98% in 2021, then tumbled 90.5% in 2024.
  • Over 5 years, Other Non-Current Assets stood at $49.2 million in 2021, then decreased by 19.15% to $39.8 million in 2022, then fell by 2.47% to $38.8 million in 2023, then dropped by 7.55% to $35.9 million in 2024, then plummeted by 95.96% to $1.4 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $1.4 million, $62.4 million, and $28.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.